𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effectived-penicillamine treatment of an early diagnosed patient with Wilson's disease

✍ Scribed by J. P. Wouwe; M. H. Weel-Sipman; M. A. H. Giesberts; D. J. Ruiter; H. H. Gelderen

Publisher
Springer
Year
1984
Tongue
English
Weight
96 KB
Volume
143
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Early treatment benefits of ropinirole p
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
✍ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 488 KB πŸ‘ 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn

A comparison of sumanirole versus placeb
A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
✍ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.

Microstructure of the non-rapid eye move
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: Effects of dopaminergic treatment
✍ Hans Brunner; Thomas C. Wetter; Birgit Hogl; Alexander Yassouridis; Claudia Tren πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 108 KB πŸ‘ 1 views

## Abstract We investigated non‐rapid eye movement (non‐REM) sleep in patients with newly diagnosed Parkinson's disease (PD) who had never previously received dopaminergic medication. There were no significant differences in the conventional sleep parameters between de novo patients with PD and a h